Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T86264
(Former ID: TTDNC00532)
|
|||||
Target Name |
Solute carrier family 40 member 1 (SLC40A1)
|
|||||
Synonyms |
SLC11A3; MSTP079; IREG1; Ferroportin-1; FPN1
Click to Show/Hide
|
|||||
Gene Name |
SLC40A1
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 5 Target-related Diseases | + | ||||
1 | Acute disease anaemia [ICD-11: 3A90] | |||||
2 | Anemia [ICD-11: 3A00-3A9Z] | |||||
3 | Myelodysplastic syndrome [ICD-11: 2A37] | |||||
4 | Myeloproliferative neoplasm [ICD-11: 2A20] | |||||
5 | Thalassaemia [ICD-11: 3A50] | |||||
Function |
Mediates iron efflux in the presence of a ferroxidase (hephaestin and/or ceruloplasmin). May be involved in iron export from duodenal epithelial cell and also in transfer of iron between maternal and fetal circulation.
Click to Show/Hide
|
|||||
BioChemical Class |
Ferroportin protein
|
|||||
UniProt ID | ||||||
Sequence |
MTRAGDHNRQRGCCGSLADYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNSLLL
TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKHEL LTMYHGWVLTSCYILIITIANIANLASTATAITIQRDWIVVVAGEDRSKLANMNATIRRI DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYVLLWKVYQKTPALAVKAGLK EEETELKQLNLHKDTEPKPLEGTHLMGVKDSNIHELEHEQEPTCASQMAEPFRTFRDGWV SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF TWLRRKCGLVRTGLISGLAQLSCLILCVISVFMPGSPLDLSVSPFEDIRSRFIQGESITP TKIPEITTEIYMSNGSNSANIVPETSPESVPIISVSLLFAGVIAARIGLWSFDLTVTQLL QENVIESERGIINGVQNSMNYLLDLLHFIMVILAPNPEAFGLLVLISVSFVAMGHIMYFR FAQNTLGNKLFACGPDAKEVRKENQANTSVV Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
1 | LY2928057 | Drug Info | Phase 2 | Anaemia | [2] | |
2 | Ferroportin mab | Drug Info | Phase 1 | Anemia | [3] | |
3 | M012 | Drug Info | Phase 1 | Myelodysplastic syndrome | [2] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | LY2928057 | Drug Info | [4] | |||
Agonist | [+] 1 Agonist drugs | + | ||||
1 | M012 | Drug Info | [5] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: (1S)-2-{[{[(2S)-2,3-Dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate | Ligand Info | |||||
Structure Description | Structure of human ferroportin bound to hepcidin and cobalt in lipid nanodisc | PDB:6WBV | ||||
Method | Electron microscopy | Resolution | 2.50 Å | Mutation | No | [6] |
PDB Sequence |
SLADYLTSAK
25 FLLYLGHSLS35 TWGDRMWHFA45 VSVFLVELYG55 NSLLLTAVYG65 LVVAGSVLVL 75 GAIIGDWVDK85 NARLKVAQTS95 LVVQNVSVIL105 CGIILMMVFL115 HKHELLTMYH 125 GWVLTSCYIL135 IITIANIANL145 ASTATAITIQ155 RDWIVVVAGE165 DRSKLANMNA 175 TIRRIDQLTN185 ILAPMAVGQI195 MTFGSPVIGC205 GFISGWNLVS215 MCVEYVLLWK 225 VYQKTPALAV235 KAGAEPFRTF295 RDGWVSYYNQ305 PVFLAGMGLA315 FLYMTVLGFD 325 CITTGYAYTQ335 GLSGSILSIL345 MGASAITGIM355 GTVAFTWLRR365 KCGLVRTGLI 375 SGLAQLSCLI385 LCVISVFMPG395 SPLPIISVSL457 LFAGVIAARI467 GLWSFDLTVT 477 QLLQENVIES487 ERGIINGVQN497 SMNYLLDLLH507 FIMVILAPNP517 EAFGLLVLIS 527 VSFVAMGHIM537 YFRFAQNTL
|
|||||
|
||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Ferroptosis | hsa04216 | Affiliated Target |
|
Class: Cellular Processes => Cell growth and death | Pathway Hierarchy | ||
Mineral absorption | hsa04978 | Affiliated Target |
|
Class: Organismal Systems => Digestive system | Pathway Hierarchy |
Degree | 3 | Degree centrality | 3.22E-04 | Betweenness centrality | 2.06E-04 |
---|---|---|---|---|---|
Closeness centrality | 1.47E-01 | Radiality | 1.19E+01 | Clustering coefficient | 0.00E+00 |
Neighborhood connectivity | 1.67E+00 | Topological coefficient | 3.33E-01 | Eccentricity | 13 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) | ||||||
Drug Resistance Mutation (DRM) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 1 KEGG Pathways | + | ||||
1 | Mineral absorption | |||||
NetPath Pathway | [+] 1 NetPath Pathways | + | ||||
1 | TGF_beta_Receptor Signaling Pathway | |||||
Reactome | [+] 1 Reactome Pathways | + | ||||
1 | Iron uptake and transport | |||||
WikiPathways | [+] 3 WikiPathways | + | ||||
1 | Iron uptake and transport | |||||
2 | Iron metabolism in placenta | |||||
3 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161. | |||||
REF 2 | Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423. | |||||
REF 3 | ClinicalTrials.gov (NCT01991483) A Study of LY2928057 in Hemodialysis Participants. U.S. National Institutes of Health. | |||||
REF 4 | Targeting the Hepcidin-Ferroportin Axis to Develop New Treatment Strategies for Anemia of Chronic Disease and Anemia of Inflammation. Am J Hematol. 2012 April; 87(4): 392-400. | |||||
REF 5 | Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794. | |||||
REF 6 | Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms. Nature. 2020 Oct;586(7831):807-811. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.